Hengrui Pharma's SHR-3201 Injection Receives Clinical Trial Approval Notice

Stock News10-13

Hengrui Pharma (600276.SH) has announced that its subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SHR-3201 Injection, and clinical trials will be initiated in the near future.

The applied indication is Alzheimer's disease. SHR-3201 Injection is a drug independently developed by the company for the treatment of AD, capable of clearing disease biomarkers in patients' brains and delaying cognitive decline.

According to available information, no similar drug has been approved for marketing either domestically or internationally. As of now, the cumulative R&D investment in SHR-3201 Injection-related projects amounts to approximately 48.8 million yuan (unaudited).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment